Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy
- 350 Downloads
Colorectal cancer (CRC) incidence has increased during the past decades in Spain, being the first malignant tumour in incidence. Observed mortality for CRC is mainly due to liver and lung metastases. The only curative treatment is surgery; new surgical techniques and neoadjuvant treatments have increased the number of surgery candidate patients. Patients should be managed with a multidisciplinary approach that includes imaging techniques, chemotherapy, surgery and pathological assessment. As an answer to this approach, a group of pathology experts interested on CRC liver metastases aimed to review the diagnosis and prognosis of liver mestastases and developed practical recommendations for its assessment. The expert group revised the current literature and prepared questions to be discussed based on available evidence and on their clinical practise. As a result, recommendations for the assessment of tumour regression of liver metastases are proposed, which could be implemented in oncology centres allowing assessment standardisation for these patients. Prospective multi-center studies to evaluate these recommendations validity will further contribute to improve the standard care of CRC liver metastases patients.
KeywordsRecommendation Colorectal cancer Liver metastases Pathological response Tumour regression grade
The authors would like to thank Eliana Mesa who has provided medical writing assistance on behalf of Springer Healthcare. The necessary scientific meetings along with medical writing services were supported financially by Roche Farma, S.A. of Spain. Roche Farma, S.A. of Spain has not had any influence on the manuscript content.
Conflict of interest
María Rosa Ortiz Duran and Esther Díaz Gómez have received clinical study grants from Roche Farma S.A. of Spain, Ricardo González-Cámpora has participated on studies supported by Novartis. All other authors declare that they do not have any conflict of interest that may inappropriately influence this work.
- 1.Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. http://onlinelibrary.wiley.com/doi/10.3322/caac.20073/pdf.
- 2.EuropaColon. Colorectal cancer statistics. http://www.europacolon.com/crcstatistics.php?Action=Crcstatistics. Accessed 9 August 2013.
- 4.Sociedad Española de Oncología Médica. El cáncer en España 2012. Cifras de cáncer, estimaciones para el año. 2012. http://www.seom.org/en/prensa/el-cancer-en-espanyacom/103644-el-cancer-en-espana-2012?showall=1. Accessed 9 August 2013.
- 5.Redondo Capafons S, Planas Giner A, Garriga Biosca R, Pla Poblador R. Neoadjuvant chemotherapy used for colorectal liver and lung metastasis resections. Farm Hosp. 2011;35(5):255, e1–5.Google Scholar
- 18.Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35(5):515–20.PubMedCrossRefGoogle Scholar
- 22.de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248(4):626–37.Google Scholar
- 25.WHO handbook for reporting results of cancer treatment who offset publication no. 48. ISBN 92 4 170043 3. Geneva: World Health Organization; 1979. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf.
- 27.Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773–82.PubMedCrossRefGoogle Scholar
- 34.Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18(2):299–304.PubMedCrossRefGoogle Scholar
- 36.Chan G, Hassanain M, Chaudhury P, Vrochides D, Neville A, Cesari M, et al. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB (Oxford). 2010;12(4):277–84.Google Scholar
- 39.Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17(11):2870–6.PubMedCrossRefGoogle Scholar
- 41.Zalinski S, Bigourdan JM, Vauthey JN. Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? (Article in French). J Chir (Paris). 2010;147(Suppl 1):S18–24.Google Scholar
- 42.Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56(4):430–9.PubMedCrossRefGoogle Scholar
- 43.Poultsides GA, Bao F, Servais EL, Hernandez-Boussard T, Dematteo RP, Allen PJ, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 2012;19(9):2797–804 (Epub 2012 Apr 3).Google Scholar